Belite Bio, Inc (BLTE)

Belite Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-36.14	-31.63	-12.65	-9.67
Depreciation & Amortization	0.45	0.4	0.2	0.03
Loss (Gain) From Sale of Assets	-	-	-	-0.01
Loss (Gain) From Sale of Investments	-0.05	-	-	-
Stock-Based Compensation	8.99	3.82	1.48	1.53
Other Operating Activities	-3.61	-	-	-
Change in Accounts Receivable	0.02	-0.02	-0.03	-
Change in Accounts Payable	0.01	-	-0.04	0.05
Change in Other Net Operating Assets	1.1	-2.41	-0.42	0.6
Operating Cash Flow	-29.23	-29.84	-11.46	-7.47
Capital Expenditures	-0.12	-0.06	-0.39	-0.07
Sale of Property, Plant & Equipment	-	-	-	0.02
Sale (Purchase) of Intangibles	-0.04	-	-	-
Investment in Securities	-110.42	-	-	-
Investing Cash Flow	-110.57	-0.06	-0.39	-0.06
Issuance of Common Stock	58.2	77.19	37.99	0.23
Other Financing Activities	25.39	-1.23	-1.03	-0.82
Financing Cash Flow	83.6	75.96	36.96	-0.58
Foreign Exchange Rate Adjustments	-0.27	0.01	-0.37	-0.16
Net Cash Flow	-56.48	46.07	24.75	-8.27
Free Cash Flow	-29.35	-29.9	-11.85	-7.55
Free Cash Flow Per Share	-0.96	-1.12	-0.59	-0.79
Cash Interest Paid	-	-	0.02	-
Cash Income Tax Paid	0.01	0.01	-	-
Levered Free Cash Flow	-13.42	-15.3	-7.1	-4.01
Unlevered Free Cash Flow	-13.4	-15.28	-7.09	-4.01
Change in Working Capital	1.13	-2.43	-0.49	0.64

Updated Mar 2, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q